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Abstract
Background: The pathogenesis of pre-eclampsia (PE)
is incompletely understood. The placenta is consid-
ered to play a key role in this disease. Recent research
showed that many microRNAs (miRNAs) are
expressed in human placenta. Our aim in this study
was to determine differential expression of miRNAs
in placenta with severe PE, and normal placenta.
Methods: Differential expression of miRNAs in pla-
centa (four severe PE and a control group of four
normal pregnant women) was first screened using
microarray analysis. Following this, some differential
miRNAs were selected and validated using real-time
quantitative reverse transcription-polymerase chain
reaction in placenta from women with severe PE
(ns24), and a healthy control group (ns26).
Results: We found the following miRNAs were signi-
ficantly increased in placenta from women with
severe PE: miR-16, miR-29b, miR-195, miR-26b, miR-
181a, miR-335 and miR-222. Gene ontology analysis
of the target genes revealed enrichment for specific
biological process categories, i.e., regulation of cel-
lular physiological process including miR-16, miR-29b,
miR-195, miR-26b and miR-335, and signal transduc-
tion including miR-181a and miR-222.
Conclusions: These different miRNAs may play an
important role in pathogenesis of PE and may
become diagnostic markers for PE.
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Introduction
Pre-eclampsia (PE) is a disease of pregnancy charac-
terized by hypertension and proteinuria, developing
after 20 weeks of gestation. It has been estimated that
5%–7% of pregnancies world wide are complicated by
this disorder, resulting in a very large disease burden
(1). Although its pathogenesis is incompletely under-
stood, the placenta is considered to play a key role in
the disease (2).
Recent studies on microRNA (miRNA) offer the
possibility for developing a new class of molecular
markers for diagnosis of PE. MiRNAs are short (19–25
nucleotides), single-stranded, and non-protein-coding
RNAs (3) that regulate gene expression by binding to
the 39 untranslated region of the target mRNAs (4).
They function in diverse biological processes, includ-
ing development, differentiation, apoptosis, and
oncogenesis (5). Moreover, recent research shows
that many miRNAs are expressed abundantly in the
human placenta (6).
Published data on miRNAs in human PE is surpris-
ingly sparse. Pineles et al. (7) first reported the miRNA
expression patterns in placentae with distinct pathol-
ogies including PE and PEqsmall-for-gestational
age (SGA). However, they only identified the expres-
sion of 157 miRNAs using quantitative real-time
reverse transcription-polymerase chain reaction (qRT-
PCR) for miRNA arrays. Roman et al. (8) reported the
differential expression of miRNA in placenta of His-
panics with severe PE. Recently, there was another
report published on miRNA in Chinese women with
PE (9). This lack of data prompted us to determine and
compare the expression profile of miRNA in placenta
of Chinese patients with PE compared with normal
placenta tissue. We wished to evaluate the potential
clinical usefulness of miRNA as diagnostic markers.
Materials and methods
Patients and tissue samples
Placental tissue was obtained from women who were hos-
pitalized in the Department of Gynecology and Obstetrics of
The Affiliated Drum Tower Hospital of Nanjing University
Medical School. Written consent was received from women
prior to surgery. The hospital Ethics Committee approved
the consent forms and the protocols for evaluation of the
tissue. All placental tissues were obtained at the time of
cesarean section. We selected 24 pregnancies complicated
by severe late-onset PE with delivery occurring after
34 weeks. Also, 26 pregnant women with normal term preg-
nancy were recruited as the control group. The relevant clin-
ical details for the patients are shown in Table 1. For the
control group, women with chronic hypertension, cardiovas-
cular disease, renal disease, hepatitis, diabetes, any evidence
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Table 1 Clinical characteristics of the study population.
PE (ns24) Control (ns26) p-Value
Age, years 28.1"1.3 28.7"1.1 NS
Gestational age at delivery, weeks 37.0"0.2 38.8"0.4 NS
% of primiparae 10 (41.6%) 15 (57.6%) NS
Body mass index, kg/m2 29.0"1.0 27.2"1.2 NS
Systolic blood pressure, mm Hg 161.5"4.1 119.6"3.9 -0.05
Diastolic blood pressure, mm Hg 113.4"2.8 81.7"3.3 -0.05
Proteinuria, mg/24 h 2209.4"23.6 0 -0.05
Alanine aminotransferase, U/L 33.9"8.6 30.5"6.5 NS
Blood urea nitrogen, mmol/L 4.1"0.3 3.8"0.2 NS
Platelet, =109/L 157.9"22.1 192.0"31.4 NS
Birth weight, g 2835.6"173.0 3415.3"158.3 NS
Placenta weight, g 485.8"25.6 526.3"28.4 NS
PE, pre-eclampsia; NS, non-significant.
of intrapartum infection or other complications of pregnancy
complications, such as fetal anomalies or chromosomal
abnormalities were excluded from this study.
PE was defined as gestational hypertension (systolic pres-
sure )140 mm Hg or diastolic blood pressure )90 mm Hg
on G2 occasions after gestational week 20) with proteinuria
()0.3 g/day). Severe PE was defined by the presence of G1
of the following: 1) severe gestational hypertension (systolic
pressure )160 mm Hg or diastolic blood pressure)110mm
Hg on G2 occasions after gestational week 20); or 2) severe
proteinuria (G5 g protein in a 24-h urine specimen) (ACOG
practice bulletin) (10). We collected chorionic tissue blocks
(;1 cm3) from the central part of the placenta only. Contam-
ination with mother decidua and amniotic membranes was
excluded by morphological observation. Tissues were thor-
oughly washed with normal saline and then frozen in liquid
nitrogen and stored at –808C until used.
RNA extraction
Total RNA included miRNA was extracted using Trizol
Reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. RNA integrity was determined
using formaldehyde denaturalization agarose gel electro-
phoresis. RNA concentrations were measured with the
smartspec plus spectrophotometer (BIO-RAD, Hercules,
CA, USA).
MicroRNA microarray analysis
Eight samples, four normal placentae (4 normal placentae
were pooled to form a control group) and four placentae
from women with severe PE (matched for gestational age at
delivery and mother age) were assayed using a miRNA
microarray chip (CapitalBio Corp, Beijing, China). We under-
took miRNA expression analysis according to their instruc-
tions. We reported only those genes with significant
(p-0.05) differential expression of G2.0-fold changes. Mi-
RNAs were further analyzed according to predicted targets
found at miRBase (http://microrna.sanger.ac.uk/targets
version 5).
Mature microRNA quantitative real-time reverse
transcription PCR (qRT-PCR)
The method to quantify mature miRNA was performed as
described previously (11). We used TaqMan MicroRNA
Assays (Applied Biosystems, Foster City, CA, USA). Total
RNA was purified using mirVana miRNA isolation kit
(Ambion, Austin, TX, USA) to enrich the small RNA fraction.
Then, 10 ng of total RNA was combined in the 15 mL RT
reaction: 1.5 mL 10=RT-PCR buffer, 1 mL of 50 U/mL Multi-
Scribe RT enzyme, 0.15 mL 100=dNTP mix, 0.19 mL 20 U/mL
RNase-inhibitor, and 3 mL 5=specific RT-primer and nucle-
ase-free water to a total volume of 15 mL. The transcription
reaction was incubated at 168C for 30 min, 428C for 30 min,
and 858C for 5 min. All reverse transcription reactions,
including no-template controls and RT minus controls, were
run in duplicate. Once the RT reactions are complete, the
PCR reactions can be assembled. For a 20-mL reaction, 10 mL
2=Universal Master Mix, 1.32 mL of the RT product, 1 mL
20=TaqMan Assay, and 7.68 mL nuclease-free water were
combined. Subsequently, qRT-PCR was performed using
an Applied BioSystems 7300 Sequence Detection System
(Perkin-Elmer Applied Biosystems, Foster City, CA, USA).
The reactions were incubated in a 96-well optical plate at
958C for 10 min, followed by 40 cycles at 958C for 15 s and
608C for 1 min. All experiments were done in triplicate. The
threshold cycle (Ct) was determined using the default thresh-
old settings. The Ct value was defined as the fractional cycle
number at which fluorescence passes a fixed threshold. The
relative amount of each miRNA to internal control was
calculated using the equation , where DCtsCtmiRNA–CtU6.– CD t2
All primers used are listed in Table 2.
Statistical analysis
Results were expressed as mean"SEM. Statistical analysis
was performed using unpaired Student’s t-test, using
GraphPad Prism 5 Demo software (GraphPad software, San
Diego, CA, USA). A p-0.05 was considered to be statistically
significant.
Results
Characteristics of RNA samples
The mean ratio of absorbance at 260 and 280 nm
(A260/A280) of all 50 RNA samples amounted to
1.93"0.05 (arithmetic mean"SD). RNA integrity was
determined using formaldehyde denaturalization aga-
rose gel electrophoresis (data not shown). The crite-
rion for RNA quality is an A260/A280 ratio )1.8 and
a clearly visible 28S and 18S rRNA band with a ratio
of 1.0;2.0 (28S:18S).
MicroRNA microarray expression data
We used the microarray platform CapitalBio Mam-
malian miRNA Array V3.0 consisting of 924 miRNA
Hu et al.: Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia 925
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probes (677 human miRNAs) corresponding to the
Sanger Center database miRBase version 10.0. First,
we assessed the expression profile in normal placenta
and placenta from women with severe PE. Several
previous in depth comparative studies between
microarray platforms and analysis procedures have
indicated the very high reproducibility, sensitivity,
and specificity of similar expression microarrays
when using the recommended procedures (12, 13).
Microarray data discussed in this publication have
been deposited in the NCBI Gene Expression Omni-
bus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are
accessible through GEO Series accession number
GSE15789. These miRNAs were retained for further
statistical analysis including SAM (14) and hierarchi-
cal cluster analysis (15) (Figure 1). After the raw data
were normalized, we found 20 miRNAs to be up-reg-
ulated and seven miRNAs down-regulated in patients
with severe PE compared with nomal placenta. The
changes in miRNA identified in placentas from
women with severe PE are shown in Table 3.
Validation of microarray data by qRT-PCR analysis
Further validation of aberrant miRNAs was deter-
mined using qRT-PCR in placentas from 24 women
with severe PE and 26 placentas from women with
normal pregnancy. We identified the seven most
up-regulated miRNAs (miR-181a, miR-195, miR-222,
miR-16, miR-29b, miR-26b and miR-335). As shown in
Figure 2, the expressions of miR-16, miR-29b, miR-
195, miR-26b, miR-181a, miR-335 and miR-222 were
significantly different in severe PE compared with
normal placenta. These miRNAs were found to have
the same expression trend as microarray analysis, but
the discordance observed was not identical. This
result was not surprising because qRT-PCR is a
more sensitive technique compared with miRNA
microarray.
Target prediction and GO analysis
Predicted targets of miRNAs differentially expressed
in this study were determined using miRBase Targets
(16) (Table 4). In addition, we used CapitalBio Mol-
ecule Annotation System V4.0 to perform gene onto-
logy (GO) analysis on the gene target lists of miR-16,
miR-29b, miR-195, miR-26b, miR-181a, miR-335 and
miR-222 and found that specific biological process
categories were enriched (Table 5).
Discussion
In the present study, we profiled the expression of a
number of miRNAs in placenta obtained from women
with severe PE and from women with normal preg-
nancy. Of the 677 human miRNAs on the array of the
expression values, 27 miRNAs were differentially
expressed between placenta from women with severe
PE and those with normal pregnancy (Table 3). There
were 20 miRNAs that were up-regulated in PE com-
pared with normal placenta, and seven miRNAs were
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Figure 1 Hierarchical cluster analysis of differentially
expressed miRNAs in placenta from women with severe pre-
eclampsia (P1, P2, P3, P4) and normal placenta (composed
of tissue from four normal placentas).
Each row represents a microRNA and each column repre-
sents a sample pair of placenta from women with severe pre-
eclampsia and normal pregnancy. The color indicates high
expression (yellow) or low expression (blue) according to the
color legend shown below. The microRNA data were clus-
tered according to their similarities in expression pattern in
microRNAs and tissues. The dendrograms display similarity
of expression among these cohorts.
Table 3 The list of miRNAs that were differentially
expressed between pre-eclampsia compared with normal
placenta.
Name Fold change
hsa-miR-181a 6.58
hsa-miR-195 4.23
hsa-miR-222 4.08
hsa-miR-16 3.65
hsa-miR-29b 3.57
hsa-miR-26b 3.24
hsa-miR-335 2.91
hsa-miR-126 2.76
hsa-miR-7f 2.68
hsa-miR-565 2.61
hsa-miR-20b 2.57
hsa-miR-27a 2.46
hsa-miR-141 2.42
hsa-miR-519b-3p 2.37
hsa-miR-451 2.34
hsa-miR-450a 2.25
hsa-miR-520g 2.20
hsa-miR-30e 2.16
hsa-miR-522 2.12
hsa-miR-486-3p 2.05
hsa-miR-214 –2.04
hsa-miR-658 –2.13
hsa-miR-532-3p –2.38
hsa-miR-423-5p –3.13
hsa-miR-491-5p –3.70
hsa-miR-612 –4.35
hsa-miR-508-5p –7.69
Figure 2 Real time PCR expression of miR-16, miR-29b,
miR-195, miR-26b, miR-181a, miR-335 and miR-222 in nor-
mal placenta and placenta from women with severe pre-
eclampsia.
Bar graphs show real time PCR expression of miR-16, miR-
29b, miR-195, miR-26b, miR-181a, miR-335 and miR-222 in
placenta from women with normal pregnancy and placenta
from women with severe pre-eclampsia. The data are pre-
sented as relative expression following normalization. Data
represent mean"SE. *Significantly different forms. p-0.05
was considered significant.
down-regulated. Several studies have reported the
differential expression of miRNA in normal placenta
and PE placenta. Pineles et al. (7) found that expres-
sion of two miRNAs (miR-210 and miR-182) was sig-
nificantly higher in PE than in the control group.
Roman et al. (8) found that there were 91 dysregulat-
ed miRNAs (38 miRNAs were down-regulated and
53 were up-regulated). Zhu et al. (9) found that 11
miRNAs were overexpressed and 23 miRNAs were
underexpressed in PE. When compared with their
results, there was no overlap with our data. This
might be attributed to the different array platforms
and ethic groups and gestation age of the placenta.
It is estimated that ;30% of genes are potential tar-
gets of miRNA function (17, 18). Since each miRNA is
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Table 4 MiRNAs and gene targets.
miRNA Chromosomal Predicted target genes
location
hsa-miR335 7q21.1 PLGF,PGR,ACVR1C,IGR2BP2,HIF1AN,COL4A2,IL-17RD,KIAA
0256,MAP3K2,EBF4,TP53NP2,ECFN2,HOXB3,VAV2,MEF2D
hsa-miR181a 9q33.3/1q31.3 TGFBRAP1,IL18R1,IL1R1,FGFR2,KIR2DL1,IL12RB1,KIAA1632,
TNFAIP6,HLA-C,HLA-B,HLA-DRA,TLR1, IL2,SAP30,TGFBI,
CD164L2,CD1E,KLRD1,IFNG,CCL7,CCL11,CCL8,MMP7
hsa-miR222 xp11.3 IL18RAP,ADAM17,ADAM8,KIAA1279,AGTPBP1,KIR3DL1,
ICAM4,HLA-F,PI16,ADAMTS16, CD180,IL17RB,ADAM22,
IFRD1,CD99,CYR61,CD68,MMP1,IL18
has-miR16 3q26.1/13q14.3 C2orf34,hcG_1790474,IL18RAP,CD40,FGFR2,FGF8,KIAA1462,
FLT3,ADAMTS18,GFER,TLE4,ADAMTSL1,CD274,CD37,CD97,
PIGB,EGFL8,TKR1,NKKB1,CXCL3,PPAP2A,CD99,TGFBR3,
CD48,ADAMTS4,IL20,VWF,CD163,CCL13,CCL4,CCL4L,
FGFR1,IL10RB,CD151,MMP3
hsa-miR26b 2q35 IL18R1,MMP21,PPA1,KIAA1279,ANGPTL2,ADAMTSL1,PEG3,
KIR3DL1,KIR2DL4,KIR2DL1,FGF21,CDC34,MAP3K2,STAT4,
PRL,EGF,IRF2,CCL26,CSFIRA,IL13RA1,KIAA2013,ETV3,CD1C,
CD1E,IL20,IFNG,CD68,CCL13,SERPINA10,MMP12
hsa-miR29b 1q32.2/7q32.3 ILIF9,PIGF,CD40,ADAMTS18,IL32,HIF3A,ADAMTS10,ANGPTL4,
TNFRSF9,KIAA0101,ADAMTS7,HLA-DQA2,VEGFA,IL20RA,
ADAMTS6,SRP19,CDC7,IL4,CD55,IFNG,IL-22,TGFB3,LPL,
CD248,MMP8
hsa-miR195 17p13.1 CD40,ADAM12,FGF8,KIAA1462,ADAMTS1,CD37,MICA,LTB,
EGFL8,VEGFA,TLR1,IL15,CXCL3,PPAP2A,ILF2,CD48,IL20,
CD163,CCL4,CCL4L1,IL10RB,MMP3HLA-DRB1
Note: see citations in the text and http://microrna.sanger.ac.uk/sequences/regardingmost updated predicted target genes.
Table 5 The results of gene ontology analysis of targets of differentially expressed miRNAs.
Biological process category, n Targets of Targets of Targets of Targets of Targets of Targets of Targets of
miR-16 miR-26b miR-29b miR-195 miR-335 miR-181a miR-222
Cell death 16 8 9 12 10 7 7
Immune system process 12 9 9 20 9 17 12
Immune response 7 5 5 8 7 5 7
Regulation of cellular physiological 44 38 33 44 45 29 29
process
Signal transduction 41 28 29 34 36 35 30
Organ development 10 12 14 14 16 13 12
System development 7 8 5 9 9 6 5
Regulation of signal transduction 6 6 5 6 4 7 5
Tissue development 5 1 3 6 5 3 3
Cell proliferation 4 3 3 5 6 4 4
Cell development 2 6 4 4 5 2 3
Values expressed as number of genes targeted by miRNA.
predicted to have a broad range of targets, even an
alteration in the expression of a single miRNA could
have a significant impact on the outcome of diverse
biological functions associated with these genes. As
such, the absence or altered expression of these and
other miRNAs could result in expression re-program-
ming of many of their target genes in PE. The increa-
sed miRNA expression in PE suggests the down-reg-
ulation of potential target genes which may contribute
to the pathology of PE. Among the genes predicted
as the target of miR-16, miR-26b, miR-29b, miR-335,
miR-222, miR-181a and miR-195 (Table 4), we found
the target genes of these miRNAs were related to
angiogenic factors, such as vascular endothelial
growth factor A (VEGF-A) and placental growth factor
(PLGF) (19) which are important for the development
of PE (see below). Furthermore, we performed GO
analysis on the target genes, and found that a consid-
erable number of genes have been identified related
to immune response, signal transduction and angio-
genesis. These are all thought to be involved in the
maintenance of pregnancy and the development of PE
(Table 5).
Perturbation of angiogenesis has been proposed as
one of the key features of PE. It is speculated that
there is an imbalance in the production of angiogenic
growth factors at the maternal-fetal interface. Recent
lines of evidence suggest that failed trophoblast inva-
sion is linked to the maternal vascular pathology
through abnormal placental production of vasculo-
genic and angiogenic factors, such as VEGF (20, 21).
Some angiogenic growth factors, such as angiopoie-
tin 2 (Ang2), PLGF, and VEGF-C, fibroblast growth
factor (FGF), interferon-g (IFN-g), and transforming
growth factor-b (TGF-b), are involved in pregnancy
(22). These molecules may be useful markers for pre-
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dicting PE (23, 24). Zhou et al. (25) demonstrated that
the expressions of VEGF-A and VEGF receptor-1 are
down-regulated in cytotrophoblasts of pre-eclamptic
placenta. Several investigations have demonstrated
that other growth factors and their receptors, such as
PLGF and insulin-like growth factor I (IGF-I) are also
dysregulated in serum or placental tissue of women
with PE (26, 27). Mo et al. (28) found that cysteine-rich
61 (CYR61) is essential for placental development
and vascular integrity. Gellhaus et al. (29) found that
CYR61 is significantly decreased in pre-eclamptic
placenta. Interestingly, our research revealed that
these angiogenic growth factors were potential tar-
gets of the altered miRNA, such as CYR61, PLGF,
VEGF-A which were targets of miR-222, miR-335 and
miR-195, respectively. Moreover, it is reported that
miRNA is strongly implicated in angiogenesis (30).
The association between PE and altered miRNA
expression suggests the possibility of a functional
role for miRNA in this disease. Our finding may pro-
vide novel targets for further investigation of the path-
ogenesis of PE and these differential miRNAs may be
potential markers for the diagnosis of PE. Moreover,
Chim et al. found that placental miRNAs represent a
novel class of fetal nucleic acid markers in maternal
plasma (31). Therefore, it will be interesting to deter-
mine whether the differential expression profiles of
miRNAs found in placenta correlates with those from
maternal plasma, especially since these may serve as
diagnostic markers of PE.
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